Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Lexeo Therapeutics (LXEO) Shares Outstanding (2022 - 2026)

Lexeo Therapeutics' Shares Outstanding history spans 2 years, with the latest figure at $26.6 million for Q4 2023.

  • On a quarterly basis, Shares Outstanding rose 1557.95% to $26.6 million in Q4 2023 year-over-year; TTM through Dec 2023 was $26.6 million, a 1557.95% increase, with the full-year FY2023 number at $26.6 million, up 1557.95% from a year prior.
  • Shares Outstanding hit $26.6 million in Q4 2023 for Lexeo Therapeutics, up from $1.6 million in the prior quarter.
  • Over the last five years, Shares Outstanding for LXEO hit a ceiling of $26.6 million in Q4 2023 and a floor of $1.6 million in Q3 2022.